BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Guimarães PO, Lopes RD, Stevens SR, Zimerman A, Wruck L, James SK, Haque G, Giraldez RRCV, Alexander JH, Alexander KP. Reporting Clinical End Points and Safety Events in an Acute Coronary Syndrome Trial: Results With Integrated Collection. J Am Heart Assoc 2017;6:e005490. [PMID: 28438739 DOI: 10.1161/JAHA.117.005490] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Hodkinson A, Kontopantelis E. Applications of simple and accessible methods for meta-analysis involving rare events: A simulation study. Stat Methods Med Res 2021;30:1589-608. [PMID: 34139915 DOI: 10.1177/09622802211022385] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Keebler D, Teng E, Chia J, Galanter J, Peake J, Tuckwell K. Regional variations in adverse event reporting rates and ACR responses in placebo/standard-of-care arms of rheumatoid arthritis trials. Rheumatology (Oxford) 2020;59:3023-31. [PMID: 32182362 DOI: 10.1093/rheumatology/keaa043] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Fanaroff AC, Haque G, Thomas B, Stone AE, Perkins LM, Wilson M, Jones WS, Melloni C, Mahaffey KW, Alexander KP, Lopes RD. Methods for safety and endpoint ascertainment: identification of adverse events through scrutiny of negatively adjudicated events. Trials 2020;21:323. [PMID: 32272961 DOI: 10.1186/s13063-020-04254-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
4 Aizpuru F. Adverse Events as End Points: The Need to Account for Both Sides of the Same Coin. J Am Heart Assoc 2017;6:e006018. [PMID: 28438742 DOI: 10.1161/JAHA.117.006018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]